Active Ingredient: Icotrokinra
ICOTYDE is indicated for the treatment of moderate to severe plaque psoriasis in adults, and adolescents 12 years of age and older and weighing at least 40 kg, who are candidates for systemic therapy.
For this indication, competent medicine agencies globally authorize below treatments:
For:
In the case that patient weight is ≥ 40 kg :
Oral, 200 milligrams icotrokinra, once daily.
The recommended dose of icotrokinra is 200 mg orally once daily on an empty stomach.
If a patient shows no evidence of therapeutic benefit after 24 weeks, treatment discontinuation should be considered. The patient's response to treatment should be evaluated on a regular basis. Some plaque psoriasis patients with initial partial response may subsequently improve with continued treatment beyond 24 weeks.
If a dose is missed, patients should be instructed to take the dose on the same day as soon as possible and then resume normal dosing schedule the following day.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.